Cardiovascular innovation
| dc.contributor.author | Axelsson, Felix | |
| dc.contributor.author | Hajas, Robert | |
| dc.contributor.author | Leijon, Emil | |
| dc.contributor.author | Stuhlhofer, Otto | |
| dc.contributor.author | Thelander, Albin | |
| dc.contributor.author | Tholén, Eric | |
| dc.contributor.department | Chalmers tekniska högskola / Institutionen för teknikens ekonomi och organisation | sv |
| dc.contributor.examiner | Bohlin, Erik | |
| dc.contributor.supervisor | Lind, Frida | |
| dc.date.accessioned | 2022-06-09T12:29:19Z | |
| dc.date.available | 2022-06-09T12:29:19Z | |
| dc.date.issued | 2022 | sv |
| dc.date.submitted | 2020 | |
| dc.description.abstract | REBOA, resuscitative endovascular balloon occlusion of the aorta, is a method used for gaining control of traumatic bleeding by occluding the aorta with an endovascular balloon. However, this procedure increases blood pressure above the occlusion point and decreases blood pressure below it; increasing the risk of cerebral hemorrhage and ischemia. This bachelor’s thesis analyzes the potential market of a new cardiovascular product, in the study referred to as λ (lambda), which is currently being developed by a project group at Sahlgrenska University Hospital in Gothenburg, Sweden. The goal of λ is to minimize the risk of cerebral hemorrhage and ischemia during a REBOA intervention, hopefully eliminating the controversy REBOA is exposed to | sv |
| dc.identifier.coursecode | TEKX04 | sv |
| dc.identifier.uri | https://hdl.handle.net/20.500.12380/304632 | |
| dc.language.iso | eng | sv |
| dc.relation.ispartofseries | TEKX04-22-17 | sv |
| dc.setspec.uppsok | Technology | |
| dc.subject | REBOA | sv |
| dc.subject | pREBOA | sv |
| dc.subject | medical innovation | sv |
| dc.subject | cardiovascular innovation | sv |
| dc.subject | market analysis | sv |
| dc.title | Cardiovascular innovation | sv |
| dc.type.degree | Examensarbete på kandidatnivå | sv |
| dc.type.uppsok | M2 |